for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie, Regenxbio enter deal to develop retinal disease therapy

Sept 13 (Reuters) - AbbVie and Regenxbio Inc have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said on Monday.

AbbVie will give Regenxbio an upfront payment of $370 million, and Regenxbio may potentially receive up to $1.38 billion in milestone payments, the companies said. (Reporting by Amruta Khandekar; Editing by Amy Caren Daniel)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up